Oncobiologics, Inc. Series B Warrant
ONSIZ
ONSIZ was delisted on the 16th of May, 2018.
9 hedge funds and large institutions have $43K invested in Oncobiologics, Inc. Series B Warrant in 2018 Q1 according to their latest regulatory filings, with 2 funds opening new positions, 1 increasing their positions, 1 reducing their positions, and 1 closing their positions.
100% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 1
72% more capital invested
Capital invested by funds: $25K → $43K (+$18K)
13% more funds holding
Funds holding: 8 → 9 (+1)
0% more repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MIM
Monashee Investment Management
Boston,
Massachusetts
|
+$983 |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$613 |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$86 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
-$4K |
| 2 |
Millennium Management
New York
|
-$236 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
CAM
1
Cormorant Asset Management
Boston,
Massachusetts
| $18K | – | – | – |
|
|
ACA
2
Avoro Capital Advisors
New York
| $12K | – | – | – |
|
|
MWNA
3
Marshall Wace North America
New York
| $6K | – | – | – |
|
|
PC
4
PointState Capital
New York
| $4K | – | – | – |
|
|
5
Millennium Management
New York
| $1K | -$236 | -6,005 | -17% |
|
|
6
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| $1K | +$613 | +15,603 | New |
|
|
MIM
7
Monashee Investment Management
Boston,
Massachusetts
| $1K | +$983 | +25,000 | New |
|
|
SM
8
Sabby Management
Miami Beach,
Florida
| – | -$4K | -199,193 | Closed |
|
|
9
UBS Group
Zurich,
Switzerland
| – | +$86 | +2,185 | +291% |
|
ONSIZ Hedge Fund Activity: Q1 2018 in Review
9 of the 4,364 institutional investors tracked by Wall St. Rank reported a position in Oncobiologics, Inc. Series B Warrant (ONSIZ) for Q1 2018, worth a combined $43K — up 72% from $25K a quarter earlier.
Buyers outnumbered sellers: 2 funds opened new ONSIZ positions and 1 closed out — a net gain of 1 holder — while 1 added to existing stakes and 1 trimmed.
The largest buyer was Monashee Investment Management, opening a new position worth an estimated $983. The largest seller was Sabby Management, exiting entirely with an estimated $4K sold.
- 9 institutional investors held Oncobiologics, Inc. Series B Warrant (ONSIZ) as of Q1 2018, up from 8 in Q4 2017.
- Funds reported $43K of Oncobiologics, Inc. Series B Warrant stock for Q1 2018, up 72% quarter-over-quarter.
- 2 funds opened new Oncobiologics, Inc. Series B Warrant positions in Q1 2018 and 1 closed out, a net change of +1 holder.
- The largest Oncobiologics, Inc. Series B Warrant buyer in Q1 2018 was Monashee Investment Management, an estimated $983 added.
- The largest Oncobiologics, Inc. Series B Warrant seller in Q1 2018 was Sabby Management, an estimated $4K sold.
Based on aggregated 13F filings for Q1 2018.